Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (NASDAQ:ALNA)

Wedbush reissued their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research note published on Thursday, October 17th, AnalystRatings.com reports. The firm currently has a $26.00 price target on the stock.

A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Allena Pharmaceuticals from a buy rating to a sell rating in a research note on Monday, October 14th. Credit Suisse Group cut their price target on Allena Pharmaceuticals from $26.00 to $7.00 and set an outperform rating for the company in a research note on Friday, September 6th. ValuEngine upgraded Allena Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Cowen restated a buy rating on shares of Allena Pharmaceuticals in a research note on Friday, August 9th. Finally, Roth Capital cut their price target on Allena Pharmaceuticals from $61.00 to $31.00 in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $17.96.

NASDAQ:ALNA traded down $0.24 during mid-day trading on Thursday, hitting $2.00. 2,552,300 shares of the company traded hands, compared to its average volume of 131,828. The stock’s fifty day moving average price is $4.61 and its 200-day moving average price is $4.66. The firm has a market cap of $138.45 million, a price-to-earnings ratio of -1.16 and a beta of 2.02. Allena Pharmaceuticals has a one year low of $1.90 and a one year high of $10.66. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.22.

Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.01). Equities analysts predict that Allena Pharmaceuticals will post -1.98 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. boosted its holdings in Allena Pharmaceuticals by 17.0% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock worth $169,000 after buying an additional 6,030 shares during the last quarter. Wedbush Securities Inc. boosted its holdings in shares of Allena Pharmaceuticals by 66.6% during the 3rd quarter. Wedbush Securities Inc. now owns 25,650 shares of the company’s stock worth $101,000 after purchasing an additional 10,250 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth approximately $116,000. Susquehanna International Group LLP acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth approximately $137,000. Finally, Paloma Partners Management Co acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth approximately $212,000. Institutional investors own 65.41% of the company’s stock.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Story: How Do I Invest in Dividend Stocks

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News